The Simple BioTech Podcast

Imagine being blind and you can see again. Imagine being paralyzed and you can move again. Imagine how amazing it would feel to be cured of cancer. Life changing would be an understatement. My guest today is the CEO of a company that is leading the way in cell therapy, a technology that can do just that; cure the blind, give movement to the paralyzed, and cure cancer. Brian Culley is the CEO of Lineage Cell Therapeutics, a publicly traded company on the NYSE. Stock ticker: LCTX
Lineage Cell Therapeutics has had some extremely promising results by using the power of Pluripotent stem cells. This was a fascinating and exciting conversation and Brian does a great job of explaining complicated subjects so the average person can understand.
If you're curious about the almost magic like power of Pluripotent stem cells, and all that they can do, than this is a must listen.
Podcast notes and transcript available here: https://simplebiotechpodcast.com/brian-culley-lineage-cell-therapeutics

-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

If you've lived in the twentieth century you've likely, at one point or another, had an attachment to a non human furry friend... and with any attachment comes the inevitable realization that our furry friend is a mere mortal... one that will age, slow down, and become frail in our life time. If this is something you dread, then this episode is for you.
In this day and age we live so closely with our pets that they've become members of the standard twentieth century family... and losing a pet is just like losing a family member. My guest today is a man that is attempting to drastically slow down the aging process of our furry best friends, and to extend the amount of healthy, happy, time that we have with them.
Nick Sinclair is the CEO of Animal Bioscience, one of the 5 daughter companies of famed David Sinclair's Life Biosciences. In this fascinating interview Nick helps explain to me just how they are tackling animal aging, how it's different than tackling human aging, how the discoveries in animal aging will actually help progress the science in human aging, and a plethora of other interesting topics. If you're interested in getting an inside look into the world of Longevity, you'll love this episode.
Podcast notes available here: https://simplebiotechpodcast.com/
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

If you're confused about NAD and it's precursors then this is the podcast for you. Dr. Joseph Baur, an Associate Professor of Physiology from University of Pennsylvania, is a leading NAD researcher. His lab currently studies metabolic and signaling pathways by which nutrient intake can influence longevity, with a particular emphasis on NAD and mTOR.
In this interview Joseph breaks down all the questions I've had (and there's a lot) about the miracle molecule, NAD. Joseph helps me to understand why it's such an important molecule, how one can boost NAD levels, and what the data tells us about the different NAD precursors, NMN & NR.
As you may or not know there is quite a bit of debate about which NAD precursors work best, and if they even work at all to boost NAD levels in a way that will extend lifespan in humans. It was an absolute pleasure to have a non biased guest on the podcast to help clear things up and explain the cold, hard science. If you've seen the hundreds of podcasts out there talking about NAD, NMN, and NR and you're still confused - this episode should help.
Podcast notes available here: https://simplebiotechpodcast.com/joseph-baur-nad-nmn-nr/
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Dr. Gregory Bailey is the CEO of Juvenescence, one of the biggest players in the Longevity industry. Dr. Bailey has a medical degree from the University of Western Ontario and practiced emergency medicine for more than 10 years before entering the world of finance. We talked about all the different things that Juvenescence is working on, as well as some great tips for investing in the capital starved longevity industry. If you want some advice from one of the top investors in the industry, make sure to give this a listen.
Juvenescence has their hands in a lot of different pies... from participating in strategic investments where they know they can add significant value as a company, to launching products like Metabolic Switch, which can instantly turn you into ketosis, due to premier this year.
The longevity industry is starved for cash, but it can be extremely daunting for someone with no formal medical training to make an intelligent investment. Dr. Bailey gives some great advice for getting around this hurdle.
It was an absolute honor to speak with Dr. Gregory Bailey, and the conversation got me more excited than ever to play whatever small part I can in the industry. As his partner Jim Mellon says, this is the greatest investment opportunity in all of human history. Don't sleep on it.
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Alex Zhavoronkov is a particularly high level human being, originally working in the field of computer science, Alex had a realization that contributing to aging and aging research would be the biggest contribution he could make for humanity. Utilizing his expertise in computer science and artificial intelligence, he began using these skills to enter the world of longevity in a significant way. Artificial intelligence will play a massive role in drug and biomarker discovery going forward and Alex's company, Insilico Medicine is leading the charge in a serious way.
It was an absolute honor to speak with Alex Zhavoronkov as he explained in simple terms
just how exciting Insilico's tech is. How it works, all the different projects they are involved in, and just how much of a financial behemoth Insilico has the potential to be. (Keep an eye out for their IPO in the next few years)
-James Ruhle, SimpleBioTechPodcast.com
Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech
If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle